As part of its expansion plans, Gujarat-headquartered drug developer Dishman Carbogen Amcis (DCAL) will invest USD 50 million in France to set up a new facility for manufacturing formulated products, mainly in the form of parenterals.
The new facility will begin commercial production from January 2023 with two manufacturing lines.
The company is expanding in France, where it already has a small facility. Now, it is setting up a greenfield (fresh) project close to the existing plant with an investment of USD 50 million for manufacturing formulated products, mainly parenterals or injectables.
The new plant is around three km away from the existing facility. Eventually, it may shift the work of the small plant to this new facility, having the capacity for four manufacturing lines. The company will be starting with two of them and the other two will be for future purpose. The commencement of commercial production is planned to start commercial from January 2023.
The company is already working on the 'corrective action plan' which it had submitted to the European drug authority to resolve the observations.